Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
Kathleen A IlesMadeline ThorntonJihye ParkMya RobersonPhilip M SpanheimerDavid W OllilaKristalyn GallagherPublished in: The American surgeon (2021)
Pandemic-driven treatment protocols provide a unique opportunity to assess the utility of bridging endocrine therapy for resectable HR+/HER2- tumors. Differences in clinical and pathologic staging were similar across groups and did not appear to be affected by receipt of NAET. Our limited cohort demonstrates this strategic therapeutic avenue can optimize health care utilization and may be a reasonable approach when delaying surgery is preferred.
Keyphrases
- radiation therapy
- locally advanced
- neoadjuvant chemotherapy
- healthcare
- minimally invasive
- sars cov
- coronavirus disease
- lymph node
- liver metastases
- coronary artery bypass
- squamous cell carcinoma
- pet ct
- rectal cancer
- combination therapy
- coronary artery disease
- acute coronary syndrome
- percutaneous coronary intervention
- social media